TTK Healthcare's Q2 EBITDA slid 29.7% YoY to ₹3.7 crore, and the shares tumbled 17% on Friday.
Revenue from operations climbed 14.6% to ₹233.4 crore, yet profit before tax fell 7.3% to ₹19.7 crore after stripping out a ₹248.2‑crore gain from the sale of EVA and GoodHome to Wipro Enterprises on September 4, 2026.
The protective‑devices segment reversed a loss, bringing in ₹65.6 crore of revenue and a ₹7.6 crore profit, while medical devices saw revenue rise to ₹29.3 crore but saw profit slide to ₹5 crore from ₹6.1 crore.
Animal‑welfare revenue grew to ₹41.2 crore, profit dipped to ₹2.9 crore, and consumer‑products sales slipped to ₹54.6 crore, ending in a ₹40.7‑lakh loss after a ₹9.6‑crore profit last year. Foods revenue hit ₹42.6 crore and profit rose to ₹4.5 crore.
TTK did not issue a forward guidance; analysts expect the company to focus on consolidating core segments after the divestiture, and the stock remains under pressure as it has fallen 13% this year.